Literature DB >> 10654099

Alzheimer's disease: past, present, and future.

P J Whitehouse1.   

Abstract

As we look to a world where more individuals will suffer from dementia, it is important to reflect on our past accomplishments as we work to create a better future. Attempts to develop better medications for Alzheimer's disease focus on symptomatic treatments for both cognitive and behavioral symptoms. Some progress has been made in the areas through use of cholinesterase inhibitors and novel neuroleptics. Quality of life is a central concept to improving our interventions and to developing more effective treatments based on our understanding of pathogenesis. In the past, almost hundred years since the pioneering work in Emil Kraepelin's laboratory that we are celebrating in this series of papers, we have come far but we have further to go.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10654099     DOI: 10.1007/pl00014173

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  3 in total

1.  Changes in Cognitive Function and Risk Factors for Cognitive Impairment of the Elderly in China: 2005-2014.

Authors:  Qilin Zhang; Yanli Wu; Tiankuo Han; Erpeng Liu
Journal:  Int J Environ Res Public Health       Date:  2019-08-09       Impact factor: 3.390

2.  Combined ligand and structure-based virtual screening approaches for identification of novel AChE inhibitors.

Authors:  Kader Şahİn; Serdar DurdaĞi
Journal:  Turk J Chem       Date:  2020-06-01       Impact factor: 1.239

3.  Responsiveness of the QUALID to Improved Neuropsychiatric Symptoms in Patients with Alzheimer's Disease.

Authors:  Hadas Benhabib; Krista L Lanctôt; Goran M Eryavec; Abby Li; Nathan Herrmann
Journal:  Can Geriatr J       Date:  2013-12-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.